Lipidomics and Redox Lipidomics Indicate Early Stage Alcohol‐Induced Liver Damage
Alcoholic fatty liver disease (AFLD) is characterized by lipid accumulation and inflammation and can progress to cirrhosis and cancer in the liver. AFLD diagnosis currently relies on histological analysis of liver biopsies. Early detection permits interventions that would prevent progression to cirr...
Saved in:
Published in | Hepatology communications Vol. 6; no. 3; pp. 513 - 525 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
01.03.2022
John Wiley and Sons Inc Wolters Kluwer Health/LWW |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Alcoholic fatty liver disease (AFLD) is characterized by lipid accumulation and inflammation and can progress to cirrhosis and cancer in the liver. AFLD diagnosis currently relies on histological analysis of liver biopsies. Early detection permits interventions that would prevent progression to cirrhosis or later stages of the disease. Herein, we have conducted the first comprehensive time‐course study of lipids using novel state‐of‐the art lipidomics methods in plasma and liver in the early stages of a mouse model of AFLD, i.e., Lieber‐DeCarli diet model. In ethanol‐treated mice, changes in liver tissue included up‐regulation of triglycerides (TGs) and oxidized TGs and down‐regulation of phosphatidylcholine, lysophosphatidylcholine, and 20‐22‐carbon‐containing lipid‐mediator precursors. An increase in oxidized TGs preceded histological signs of early AFLD, i.e., steatosis, with these changes observed in both the liver and plasma. The major lipid classes dysregulated by ethanol play important roles in hepatic inflammation, steatosis, and oxidative damage. Conclusion: Alcohol consumption alters the liver lipidome before overt histological markers of early AFLD. This introduces the exciting possibility that specific lipids may serve as earlier biomarkers of AFLD than those currently being used. |
---|---|
Bibliography: | These authors contributed equally to this work. Supported by the National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism (#R21AA028432, #R24AA022057 to V.V.). Potential conflict of interest: Dr. Thompson owns stock in Medtronic. Dr. Vasilis and Dr. Chen received grants from the National Institutes of Health. The other authors have nothing to report. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Article updated on XX December 2021 after first online publication: The spelling of Vasilis Vasiliou's last name was corrected. |
ISSN: | 2471-254X 2471-254X |
DOI: | 10.1002/hep4.1825 |